NPS Pharmaceuticals, Inc. (NPSP) Reports Third Quarter 2007 Financials
NPS Pharmaceuticals (NPSP) reported company financial results for the quarter ended September 30, 2007 and also provided an update on company milestones and financial guidance. The company announced that they have: 1. Completed the Phase 3 study of GATTEX in short bowel syndrome 2. Retired substantially all of its 2008 convertible debt 3. Reduced cash burn guidance to $70-$80 million from previous guidance of $80-$90 million 4. Positioned the company to burn between $35 and $45 million in 2008 5. Explored the development of PREOS and GATTEX in at least one new indication for each program. Dr. Tony Coles, president…